Off-label Anwendung einer Budesonidhaltigen Suspension für die Behandlung einer lymphozytären Ösophagitis
Standard
Off-label Anwendung einer Budesonidhaltigen Suspension für die Behandlung einer lymphozytären Ösophagitis. / Paparoupa, Maria; Linnemüller, Stephan; Schuppert, Frank.
In: Z GASTROENTEROL, Vol. 55, No. 11, 08.2017.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Off-label Anwendung einer Budesonidhaltigen Suspension für die Behandlung einer lymphozytären Ösophagitis
AU - Paparoupa, Maria
AU - Linnemüller, Stephan
AU - Schuppert, Frank
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2017/8
Y1 - 2017/8
N2 - Background Lymphocytic esophagitis (LyE) is a rare chronic inflammatory disease of the esophagus, which shares clinical characteristics with the eosinophilic esophagitis. The most important part of its treatment is proton pump inhibitors (PPIs). Referring to locally acting steroids, evidence-based treatment strategies are missing. Case Report A 62-year-old patient presented for evaluation of his chronic dysphagia with previously diagnosed multiple oesophageal stenoses. Endoscopy revealed diffusely distributed esophageal rings and furrows and the diagnosis of LyE was established after immunohistochemical analysis of multiple mucosal biopsies. We initiated therapy with budesonide in the form of capsules (Entocort 3 × 3 mg Hartkapseln(®) once daily). During the course of the treatment, we initiated the off-label use of suspensions (Budenobronch(®) 0.5 mg twice daily) routinely used in the treatment of patients with asthma or COPD to increase the patient΄s acceptance of this therapy which was diminished because of his dysphagia. Under this therapy, clinical and later histological remission was achieved. Conclusion Our case report is meant to describe an empirical therapeutic concept, which led to clinical and histological remission of chronic LyE.
AB - Background Lymphocytic esophagitis (LyE) is a rare chronic inflammatory disease of the esophagus, which shares clinical characteristics with the eosinophilic esophagitis. The most important part of its treatment is proton pump inhibitors (PPIs). Referring to locally acting steroids, evidence-based treatment strategies are missing. Case Report A 62-year-old patient presented for evaluation of his chronic dysphagia with previously diagnosed multiple oesophageal stenoses. Endoscopy revealed diffusely distributed esophageal rings and furrows and the diagnosis of LyE was established after immunohistochemical analysis of multiple mucosal biopsies. We initiated therapy with budesonide in the form of capsules (Entocort 3 × 3 mg Hartkapseln(®) once daily). During the course of the treatment, we initiated the off-label use of suspensions (Budenobronch(®) 0.5 mg twice daily) routinely used in the treatment of patients with asthma or COPD to increase the patient΄s acceptance of this therapy which was diminished because of his dysphagia. Under this therapy, clinical and later histological remission was achieved. Conclusion Our case report is meant to describe an empirical therapeutic concept, which led to clinical and histological remission of chronic LyE.
KW - English Abstract
KW - Journal Article
U2 - 10.1055/s-0043-117187
DO - 10.1055/s-0043-117187
M3 - SCORING: Zeitschriftenaufsatz
C2 - 28787751
VL - 55
JO - Z GASTROENTEROL
JF - Z GASTROENTEROL
SN - 0044-2771
IS - 11
ER -
